Patents by Inventor Stacey Morrow

Stacey Morrow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240150850
    Abstract: Assays and methods for detecting resistance to beta-lactam antibiotics including detection of multiple ?-lactamase family specific gene targets by polymerase chain reaction or microarray. One or more kits including primers and/or probes for identification of ?-lactamase genes selected from the group consisting of one or more of the following: MOX-like, FOX-like, ACC-like, ACT/MIR-like, CMY-2-like, DHA-like, CTX-M-14-like, CTX-M-15-like, VIM-like, NDM-like, IMP-like, KPC-like, and OXA-48-like, OXA-51-like, OXA-143-like, OXA-58-like, OXA-23-like, OXA-24/40-like, TEM-like, and SHV-like. A kit may also include one or more primers and/or probes for the identification a non-beta lactamase gene family which confers antibiotic resistance, such as the MCR-1 gene.
    Type: Application
    Filed: June 9, 2023
    Publication date: May 9, 2024
    Inventors: Maria Torres-Gonzalez, Nancy Hanson, Joel Lechner, Stephanie Cossette, Cathy Scheer, Matthew R. Kreifels, Stacey Morrow, Christopher Connelly, Laura R. Porter, Randy Fowler
  • Patent number: 11708614
    Abstract: Assays and methods for detecting resistance to beta-lactam antibiotics including detection of multiple ?-lactamase family specific gene targets by polymerase chain reaction or microarray. One or more kits including primers and/or probes for identification of ?-lactamase genes selected from the group consisting of one or more of the following: MOX-like, FOX-like, ACC-like, ACT/MIR-like, CMY-2-like, DHA-like, CTX-M-14-like, CTX-M-15-like, VIM-like, NDM-like, IMP-like, KPC-like, and OXA-48-like, OXA-51-like, OXA-143-like, OXA-58-like, OXA-23-like, OXA-24/40-like, TEM-like, and SHV-like. A kit may also include one or more primers and/or probes for the identification a non-beta lactamase gene family which confers antibiotic resistance, such as the MCR-1 gene.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: July 25, 2023
    Assignees: STRECK LLC, CREIGHTON UNIVERSITY
    Inventors: Maria Torres-Gonzalez, Nancy Hanson, Joel Lechner, Stephanie Cossette, Cathy Scheer, Matthew R. Kreifels, Stacey Morrow, Christopher Connelly, Laura R. Porter, Randy Fowler
  • Publication number: 20190330685
    Abstract: Assays and methods for detecting resistance to beta-lactam antibiotics including detection of multiple ?-lactamase family specific gene targets by polymerase chain reaction or microarray. One or more kits including primers and/or probes for identification of ?-lactamase genes selected from the group consisting of one or more of the following: MOX-like, FOX-like, ACC-like, ACT/MIR-like, CMY-2-like, DHA-like, CTX-M-14-like, CTX-M-15-like, VIM-like, NDM-like, IMP-like, KPC-like, and OXA-48-like, OXA-51-like, OXA-143-like, OXA-58-like, OXA-23-like, OXA-24/40-like, TEM-like, and SHV-like. A kit may also include one or more primers and/or probes for the identification a non-beta lactamase gene family which confers antibiotic resistance, such as the MCR-1 gene.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 31, 2019
    Inventors: Maria Torres, Nancy Hanson, Joel Lechner, Stephanie Cossette, Cathy Scheer, Matthew R. Kreifels, Stacey Morrow, Christopher Connelly, Laura R. Porter, Randy Fowler
  • Patent number: RE49908
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: April 9, 2024
    Assignee: MedImmune, LLC
    Inventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst